CRL · 10-Q · 2026Q3 · Full report

Capital Expenditures

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-11-04 · Importance 24 · Surprise 14

Capital expenditures were $133.8 million for the nine months ended September 26, 2026, compared with $130.2 million in the same 2025 period. Investing activities used $369.5 million, including $467.3 million for acquisitions and assets, partly offset by $176.6 million of proceeds from business and asset sales. The Cambodian NHP Supplier and PathoQuest acquisitions, together with capital expenditures, were the principal investing cash uses; European Discovery Services and Wilmington asset-sale proceeds partly offset them.

Key facts

• Capital expenditures were $133.8 million in the nine months ended September 26, 2026, compared with $130.2 million in the comparable 2025 period. source